Healthcare -
Biotechnology - NASDAQ - US
$ 0.29
-1.11 %
$ 20.6 M
Market Cap
-0.77
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Ovid Therapeutics Inc.
| Current Assets | 55.9 M |
| Cash & Short-Term Investments | 53.1 M |
| Receivables | 0 |
| Other Current Assets | 2.86 M |
| Non-Current Assets | 36.2 M |
| Long-Term Investments | 21 M |
| PP&E | 13.2 M |
| Other Non-Current Assets | 2.02 M |
| Current Liabilities | 10.5 M |
| Accounts Payable | 3.19 M |
| Short-Term Debt | 1.34 M |
| Other Current Liabilities | 6 M |
| Non-Current Liabilities | 13.4 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 13.4 M |
EFFICIENCY
Earnings Waterfall
Ovid Therapeutics Inc.
| Revenue | 566 K |
| Cost Of Revenue | 0 |
| Gross Profit | 566 K |
| Operating Expenses | 62.5 M |
| Operating Income | -61.9 M |
| Other Expenses | -35.5 M |
| Net Income | -26.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ovid Therapeutics Inc.
| Net Income | -26.4 M |
| Depreciation & Amortization | 613 K |
| Capital Expenditures | -71 K |
| Stock-Based Compensation | 6.28 M |
| Change in Working Capital | -150 K |
| Others | -35.9 M |
| Free Cash Flow | -56 M |
Wall Street Analysts Price Targets
Ovid Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for OVID of $7.33 , with forecasts ranging from
a
low of
$3 to a high of $11 .
OVID Lowest Price Target
Wall Street Target
3 USD
934.48%
OVID Average Price Target
Wall Street Target
7.33 USD
2428.74%
OVID Highest Price Target
Wall Street Target
11 USD
3693.10%
4. DIVIDEND
ANALYSIS
OVID does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Ovid Therapeutics Inc.
Sold
0-3 MONTHS
5.14 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
4.97 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.
zacks.com
- 1 month ago
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability OV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025 Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of 2026 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.
globenewswire.com
- 1 month ago
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors.
globenewswire.com
- 2 months ago
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
globenewswire.com
- 2 months ago
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET.
globenewswire.com
- 2 months ago
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
zacks.com
- 5 months ago
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy.
globenewswire.com
- 7 months ago
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 8 months ago
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 8 months ago
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 8 months ago
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 8 months ago
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 8 months ago
8. Profile
Summary
Ovid Therapeutics Inc. OVID
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 20.6 M
Dividend Yield
0.00%
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Contact
1460 Broadway, New York, NY, 10036
https://www.ovidrx.com
IPO
Date
May 5, 2017
Employees
23
Officers
Mr. Zhong Zhong Ph.D.
Chief Scientific Officer
Dr. Manal Morsy M.B.A., M.D., PH.D.
Chief Regulatory Officer
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Chief Executive Officer & Chairman
Mr. Tom Parry
Vice President of Research and Early Development
Ms. Meg Alexander
President & Chief Operating Officer
Mr. Jeffrey A. Rona
Chief Business and Financial Officer
Dr. Toshiya Nishi D.V.M.
Head of Epilepsy Research
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Development
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Ms. Victoria Fort
Senior Vice President of Corporate Affairs & Corporate Strategy